Showing Results for: “diabetes exercise”

The American Diabetes Association ® (ADA) is proud to announce that its strong financial health and ongoing accountability and transparency have earned it a Four-Star Rating from Charity Navigator. This rating designates the ADA as an official “Give with Confidence” charity, indicating that the ADA is using its donations effectively based on Charity Navigator’s criteria. Charity Navigator is America’s largest and most utilized independent charity evaluator. Since 2001, the organization has been an unbiased and trusted source of information for more than 11 million donors annually. Charity

Findings Indicate Improvements in Mental and Physical Health as well as a Reduction in Healthcare Costs For People Living with Type 1 Diabetes Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented today at the 83rd Scientific Sessions of the American Diabetes Association ® (ADA) in San Diego, CA. As the number of diabetes cases continues to rise, addressing mental health challenges is a critical element in helping individuals with diabetes manage their care plan. Diabetes distress (DD) for

“ The American Diabetes Association ® (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. We applaud Eli Lilly for taking the important step to limit cost-sharing for its insulin, and we encourage other insulin manufacturers to do the same. While we have been able to help achieve significant progress on the issue of insulin affordability, including Medicare’s new out-of-pocket cost cap on insulin, state copay caps, and patient assistance developments from insulin manufacturers, we know that

New guidelines include most substantial changes since standards first introduced, including easier documentation of services and clarity around reporting outcomes New updates to the National Standards for Diabetes Self-Management Education and Support (National Standards) call for addressing health equity by improving access to diabetes self-management education and support (DSMES) services, a renewed focus on increasing and maintaining person-centered care and reducing administrative burden. Issued by the American Diabetes Association ® (ADA) and the Association of Diabetes Care & Education

American Diabetes Association and DaVita launch a digital experience with resources for preventing and managing diabetes-related kidney complications The American Diabetes Association ® (ADA), along with DaVita, are excited to announce the launch of an interactive digital experience aimed at helping those living with diabetes prevent and manage kidney disease. Diabetes affects one in seven adults in the U.S.—and is the number one cause of chronic kidney disease (CKD). Committed to providing the education and resources needed to combat diabetes-related health complications, the ADA recently

The American Diabetes Association ® (ADA), the leading global diabetes research, advocacy, and education organization, applauds U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME) for introducing legislation today during a joint press conference on Capitol Hill in Washington, D.C., which aims to make insulin more affordable for millions of Americans with diabetes who rely on the drug to live. The bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act includes important reforms to reduce the price of insulin by incentivizing lower list prices and

Today, the American Diabetes Association ® (ADA) published important updates to the Standards of Medical Care in Diabetes—2022 (Standards of Care) , in annotations as the Living Standards of Care . Changes include new data on: Finerenone and its effects in people with type 2 diabetes and chronic kidney disease on cardiovascular outcome SGLT2 inhibitors and their effects in people with type 2 diabetes on heart failure and renal outcomes New information on calculating eGFR and inclusion of race for kidney disease diagnosis These amendments were driven by recently published research and were

CEO Tracey D. Brown Calls on Congress to Take Aggressive Steps to Make Insulin and Other Diabetes Medications More Affordable The American Diabetes Association® (ADA) last week recommended urgent federal action to bring down skyrocketing drug prices before the Senate Health, Education, Labor and Pensions (HELP) Committee. In a statement for the congressional record submitted in conjunction with the HELP Committee’s Primary Health and Retirement Security Subcommittee’s recent hearing exploring reasons the U.S. pays the highest prices in the world for prescription medications, ADA CEO Tracey D

As part of the Biden administration’s plan to review Trump executive actions on health care, the U.S. Department of Health and Human Services (HHS) announced a delay in implementation of the “rebate rule,” moving the effective date from January 1, 2022, to January 1, 2023. The Trump administration announced its rebate proposal in 2018. The proposed rule would have effectively banned the rebates drug manufacturers give to pharmacy benefit managers in Medicare Part D—Medicare’s prescription drug program—only allowing rebates at the point of sale in an effort to reduce patients’ out-of-pocket

Last night Congress took an important step toward COVID-19 management and recovery, addressing health disparities and funding crucial diabetes research programs. The diabetes community has been disproportionately affected by this pandemic, and the American Diabetes Association® (ADA) is pleased that Americans with diabetes will soon see some relief during these difficult and extraordinary times. Although there’s still much more to be done to support those facing a heightened risk during this unprecedented public health and economic crisis – including ensuring continuity of health insurance